Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors

Bertaglia, Valentina; Petrelli, Fausto; Porcu, Michele; Saba, Luca; Pearce, Josie; Luciani, Andrea; Solinas, Cinzia; Scartozzi, Mario

doi:10.1016/j.cytogfr.2022.07.009

Cited by 6 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of non-target tumors, in sequential treatment, the 1-year DM rate of arm C was lower than arm B, whereas at the 3-year DM rate, arm B was lower than arm C (Figure 4). These data show that patients may have experienced lymphopenia, decreased lymphocyte proliferation capacity, and loss of inflammatory cytokine production capacity immediately after the treatment [46,51].…”

Section: Discussionmentioning

confidence: 72%

Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma

Kang,

Shin,

Kim

et al. 2024

Bioengineering

View full text Add to dashboard Cite

The impact of yttrium 90 radioembolization (Y90-RE) in combination with immune checkpoint inhibitors (ICIs) has recently gained attention. However, it is unclear how sequencing and dosage affect therapeutic efficacy. The purpose of this study was to develop a mathematical model to simulate the synergistic effects of Y90-RE and ICI combination therapy and find the optimal treatment sequences and dosages. We generated a hypothetical patient cohort and conducted simulations to apply different treatments to the same patient. The compartment of models is described with ordinary differential equations (ODEs), which represent targeted tumors, non-targeted tumors, and lymphocytes. We considered Y90-RE as a local treatment and ICIs as a systemic treatment. The model simulations show that Y90-RE and ICIs administered simultaneously yield greater benefits than subsequent sequential therapy. In addition, applying Y90-RE before ICIs has more benefits than applying ICIs before Y90-RE. Moreover, we also observed that the median PFS increased up to 31~36 months, and the DM rates at 3 years decreased up to 36~48% as the dosage of the two drugs increased (p < 0.05). The proposed model predicts a significant benefit of Y90-RE with ICIs from the results of the reduced irradiated tumor burden and the associated immune activation and suppression. Our model is expected to help optimize complex strategies and predict the efficacy of clinical trials for HCC patients.

show abstract

Section: Discussionmentioning

confidence: 72%

Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma

Kang,

Shin,

Kim

et al. 2024

Bioengineering

View full text Add to dashboard Cite

show abstract

“…Immunotherapy research for BRCA mainly focuses on vaccines, chimeric antigen receptor T cell (CAR-T) therapy, and immune checkpoint inhibitors [ 29 , 30 ]. ICIs have received the most attention, and many exploratory studies have been carried out clinically and fundamentally [ 31 ]. However, the effect of ICIs as a single treatment strategy in BRCA could be better, and its combination therapy is the main direction of current treatment [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy

Zhong,

Chang,

Pei

et al. 2024

Aging

View full text Add to dashboard Cite

Despite the advent of precision therapy for breast cancer (BRCA) treatment, some individuals are still unable to benefit from it and have poor survival prospects as a result of the disease’s high heterogeneity. Cell senescence plays a crucial role in the tumorigenesis, progression, and immune regulation of cancer and has a major impact on the tumor microenvironment. To find new treatment strategies, we aimed to investigate the potential significance of cell senescence in BRCA prognosis and immunotherapy. We created a 9-gene senescence-related signature. We evaluated the predictive power and the role of signatures in the immune microenvironment and infiltration. In vitro tests were used to validate the expression and function of the distinctive critical gene ACTC1. Our risk signature allows BRCA patients to receive a Predictive Risk Signature (PRS), which may be used to further categorize a patient's response to immunotherapy. Compared to conventional clinicopathological characteristics, PRS showed strong predictive efficacy and precise survival prediction. Moreover, PRS subgroups were examined for altered pathways, mutational patterns, and possibly useful medicines. Our research offers suggestions for incorporating senescence-based molecular classification into risk assessment and ICI therapy decision-making.

show abstract

Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer

Shao

2023

Clin Transl Oncol

View full text Add to dashboard Cite

Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors

Cited by 6 publications

References 39 publications

Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma

Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma

Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy

Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer

Contact Info

Product

Resources

About